Published in Inflamm Bowel Dis on September 01, 2004
European evidence based consensus on the diagnosis and management of Crohn's disease: special situations. Gut (2006) 1.87
Health determining concepts important to people with Crohn's disease and their coverage by patient-reported outcomes of health and wellbeing. J Crohns Colitis (2013) 0.83
Healthcare maintenance in elderly patients with inflammatory bowel disease. Ann Gastroenterol (2017) 0.75
Assessment of the need for psychosomatic care in patients with suspected cardiac disease. Wien Klin Wochenschr (2016) 0.75
Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med (2005) 14.50
Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med (2010) 12.35
Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology (2011) 5.38
A chromosome 8 gene-cluster polymorphism with low human beta-defensin 2 gene copy number predisposes to Crohn disease of the colon. Am J Hum Genet (2006) 5.10
Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score. Arthritis Res Ther (2005) 4.86
Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab. Gastroenterology (2009) 3.73
Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current management. J Crohns Colitis (2012) 3.69
The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Special situations. J Crohns Colitis (2009) 3.66
Core outcome domains for controlled trials and clinical recordkeeping in eczema: international multiperspective Delphi consensus process. J Invest Dermatol (2010) 3.09
Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. Gastroenterology (2011) 2.96
Non-selective betablocker therapy decreases intestinal permeability and serum levels of LBP and IL-6 in patients with cirrhosis. J Hepatol (2012) 2.93
Temporal bacterial community dynamics vary among ulcerative colitis patients after fecal microbiota transplantation. Am J Gastroenterol (2013) 2.85
Remission and active disease in rheumatoid arthritis: defining criteria for disease activity states. Arthritis Rheum (2005) 2.76
The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response? Am J Gastroenterol (2010) 2.74
The value of serologic markers in indeterminate colitis: a prospective follow-up study. Gastroenterology (2002) 2.58
Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 1: definitions and diagnosis. J Crohns Colitis (2012) 2.55
Spontaneous viral clearance in patients with acute hepatitis C can be predicted by repeated measurements of serum viral load. Hepatology (2003) 2.54
Antiendomysial and antihuman recombinant tissue transglutaminase antibodies in the diagnosis of coeliac disease: a biopsy-proven European multicentre study. Eur J Gastroenterol Hepatol (2005) 2.49
Development of the Crohn's disease digestive damage score, the Lémann score. Inflamm Bowel Dis (2010) 2.20
Impact of depressive mood on relapse in patients with inflammatory bowel disease: a prospective 18-month follow-up study. Psychosom Med (2004) 2.10
Clinical disease activity, C-reactive protein normalisation and mucosal healing in Crohn's disease in the SONIC trial. Gut (2013) 2.03
Adalimumab induces and maintains mucosal healing in patients with Crohn's disease: data from the EXTEND trial. Gastroenterology (2012) 2.03
Endoscopic ultrasound guided therapy of benign and malignant biliary obstruction: a case series. Am J Gastroenterol (2005) 1.90
Developing an instrument to assess the endoscopic severity of ulcerative colitis: the Ulcerative Colitis Endoscopic Index of Severity (UCEIS). Gut (2011) 1.80
Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 3: special situations. J Crohns Colitis (2012) 1.71
Portal pressure predicts outcome and safety of antiviral therapy in cirrhotic patients with hepatitis C virus infection. Clin Gastroenterol Hepatol (2011) 1.70
Groups IV, V, and X phospholipases A2s in human neutrophils: role in eicosanoid production and gram-negative bacterial phospholipid hydrolysis. J Biol Chem (2001) 1.67
Anti-Saccharomyces cerevisiae antibodies: a stable marker for Crohn's disease during steroid and 5-aminosalicylic acid treatment. Am J Gastroenterol (2003) 1.54
Clinical presentation of venous thromboembolism in inflammatory bowel disease. J Crohns Colitis (2012) 1.49
Citrate pharmacokinetics and metabolism in cirrhotic and noncirrhotic critically ill patients. Crit Care Med (2003) 1.44
Heterogeneous expression and regulation of CD40 in human hepatocellular carcinoma. Eur J Gastroenterol Hepatol (2003) 1.40
World Gastroenterology Organisation Global Guidelines: probiotics and prebiotics October 2011. J Clin Gastroenterol (2012) 1.39
The effects of infliximab therapy on health-related quality of life in ulcerative colitis patients. Am J Gastroenterol (2007) 1.39
Delays in assessment of patients with rheumatoid arthritis: variations across Europe. Ann Rheum Dis (2011) 1.39
Aortic mural thrombi in patients with inflammatory bowel disease: report of two cases and review of the literature. Inflamm Bowel Dis (2004) 1.35
European evidence-based Consensus on the management of ulcerative colitis: Special situations. J Crohns Colitis (2008) 1.34
Psychological interventions for treatment of inflammatory bowel disease. Cochrane Database Syst Rev (2011) 1.33
Subclinical impairment of brain function in chronic hepatitis C infection. J Hepatol (2002) 1.28
Genetic variants of Wnt transcription factor TCF-4 (TCF7L2) putative promoter region are associated with small intestinal Crohn's disease. PLoS One (2009) 1.24
Inflammatory bowel disease is a risk factor for recurrent venous thromboembolism. Gastroenterology (2010) 1.23
IP-10 correlates with hepatitis C viral load, hepatic inflammation and fibrosis and predicts hepatitis C virus relapse or non-response in HIV-HCV coinfection. Antivir Ther (2008) 1.22
Optimising monitoring in the management of Crohn's disease: a physician's perspective. J Crohns Colitis (2013) 1.20
Toll-like receptor 4 and NOD2/CARD15 mutations in Hungarian patients with Crohn's disease: phenotype-genotype correlations. World J Gastroenterol (2005) 1.19
A patient-derived and patient-reported outcome measure for assessing psoriatic arthritis: elaboration and preliminary validation of the Psoriatic Arthritis Impact of Disease (PsAID) questionnaire, a 13-country EULAR initiative. Ann Rheum Dis (2014) 1.17
Hepatocellular fat accumulation and low serum cholesterol in patients infected with HCV-3a. Am J Gastroenterol (2002) 1.17
Uveitis- a rare disease often associated with systemic diseases and infections- a systematic review of 2619 patients. Orphanet J Rare Dis (2012) 1.17
Sudden hearing loss in patients with chronic hepatitis C treated with pegylated interferon/ribavirin. Am J Gastroenterol (2004) 1.16
Rapid suppression of hematopoiesis by standard or pegylated interferon-alpha. Gastroenterology (2002) 1.14
IBD Around the world: comparing the epidemiology, diagnosis, and treatment: proceedings of the World Digestive Health Day 2010--Inflammatory Bowel Disease Task Force meeting. Inflamm Bowel Dis (2011) 1.14
Reliability and initial validation of the ulcerative colitis endoscopic index of severity. Gastroenterology (2013) 1.14
Transjugular intrahepatic portosystemic shunt for treatment of portal hypertension due to extramedullary hematopoiesis in idiopathic myelofibrosis. Blood (2002) 1.12
Diagnostic value of CT enteroclysis compared with conventional enteroclysis in patients with Crohn's disease. AJR Am J Roentgenol (2005) 1.11
Survival in patients undergoing transjugular intrahepatic portosystemic shunt: ePTFE-covered stentgrafts versus bare stents. Hepatology (2003) 1.11
Interleukin 13 and its role in gut defence and inflammation. Gut (2012) 1.08
Rapid recurrence of IBD-associated anemia and iron deficiency after intravenous iron sucrose and erythropoietin treatment. Am J Gastroenterol (2009) 1.07
Intestinal microbiota: a source of novel biomarkers in inflammatory bowel diseases? Best Pract Res Clin Gastroenterol (2013) 1.06
Remission by composite scores in rheumatoid arthritis: are ankles and feet important? Arthritis Res Ther (2007) 1.05
Measuring health in patients with fibromyalgia: content comparison of questionnaires based on the International Classification of Functioning, Disability and Health. Arthritis Rheum (2008) 1.04
Development of healthcare quality indicators for rheumatoid arthritis in Europe: the eumusc.net project. Ann Rheum Dis (2013) 1.04
Specific systemic nonviral gene delivery to human hepatocellular carcinoma xenografts in SCID mice. Hepatology (2002) 1.04
Validation of endoscopic activity scores in patients with Crohn's disease based on a post hoc analysis of data from SONIC. Gastroenterology (2013) 1.03
Which patients with IBD need psychological interventions? A controlled study. Inflamm Bowel Dis (2008) 1.03
Prevalence and clinical impact of endoscopic pseudomembranes in patients with inflammatory bowel disease and Clostridium difficile infection. J Crohns Colitis (2009) 1.02
Sorafenib attenuates the portal hypertensive syndrome in partial portal vein ligated rats. J Hepatol (2009) 1.01
A multicenter assessment of liver toxicity by MRI and biopsy in IBD patients on 6-thioguanine. J Hepatol (2005) 1.00
Adalimumab produces clinical remission and reduces extraintestinal manifestations in Crohn's disease: results from CARE. Inflamm Bowel Dis (2011) 1.00
Infliximab or cyclosporine as rescue therapy in hospitalized patients with steroid-refractory ulcerative colitis: a retrospective observational study. Inflamm Bowel Dis (2011) 1.00
Infliximab: lack of efficacy on perforating complications in Crohn's disease. Inflamm Bowel Dis (2004) 0.99
Effect of iron therapy on platelet counts in patients with inflammatory bowel disease-associated anemia. PLoS One (2012) 0.99
Research in hand osteoarthritis: time for reappraisal and demand for new strategies. An opinion paper. Ann Rheum Dis (2007) 0.99